What are the current FDA-approved Lung Cancer Treatments?
Learn more about the FDA-Approved Lung Cancer Treatments
The two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) have different treatment pathways. Today, using genetic information about tumor type and what stage the disease is at allows healthcare teams to create personalized cancer treatments for lung cancer patients. These individualized treatments may help patients avoid treatments that are unlikely to work and help to decrease the side effects of treatment. These FDA-approved treatments are grouped as Chemotherapy,Combination Therapy, Immunotherapy and Targeted Therapy.
Here are the current FDA-approved lung cancer treatments being used. Click on the treatment to see more details about the specific drug. Select a biomarker to see available treatment options.
The Future of Lung Cancer Treatments: Clinical Trials
Breakthroughs in research are happening at a faster pace leading to new FDA-approved treatments. These current lung cancer treatments and other personalized approaches to lung cancer treatment are not only improving a patient’s quality of life, but are even prolonging lives.
Many of today’s life-lengthening treatments are based on results from previous clinical trials. Clinical trials are research studies that help to determine whether new treatments are safe and effective, or better than existing treatments.
Because of progress made through clinical trials, many people with cancer are living longer and better. The conversation has changed to discussion on lung cancer – treating it as a manageable disease. Researchers need to find new therapies for patients whose cancer has recurred following standard lung cancer treatment.
* The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only.